Clinicopathological characterisation of small (2 cm or less) proximal and distal gastric carcinomas in a Chinese population

Citation
Huang, Q., J. Shi, Q. Sun, J. S. Gold, J. Chen, H. Wu, H. Yu, et al. 2015. “Clinicopathological characterisation of small [2 cm or less] proximal and distal gastric carcinomas in a Chinese population.” Pathology 47 (6): 526-532. doi:10.1097/PAT.0000000000000276. http://dx.doi.org/10.1097/PAT.0000000000000276.

Published Version
doi:10.1097/PAT.0000000000000276

Permanent link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:24983924

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA

Share Your Story
The Harvard community has made this article openly available. Please share how this access benefits you. Submit a story.

Accessibility
Clinicopathological characterisation of small (2 cm or less) proximal and distal gastric carcinomas in a Chinese population

QIN HUANG1,2,3, JONG SHI1, QU SUN1, JASON S. GOLD3,4, JIEYU CHEN1, HONGYAN WU1, HUPING YU1, YIFEN ZHANG1, HIROSHI MASIMIH3,5, CHENGGONG YU6, TRAVIS MANASCO7, WENYAN GUAN1 and GREGORY Y. LAUwers3,8

1Department of Pathology, the Nanjing Drum Tower Hospital, Nanjing, China; 2Department of Pathology and Laboratory Medicine, Veterans Affairs Boston Healthcare System, West Roxbury, 3Harvard Medical School, Boston, 4Department of Surgery, Veterans Affairs Boston Healthcare System, West Roxbury, 5Department of Gastroenterology, Veterans Affairs Boston Healthcare System, West Roxbury, MA, United States; 6Department of Gastroenterology, the Nanjing Drum Tower Hospital, Nanjing, China; 7Department of Emergency Medicine, Boston Medical Center, Boston, and 8Department of Pathology, Massachusetts General Hospital, Boston, MA, United States

Summary
Clinicopathological characteristics of small gastric carcinoma have not been well defined in Chinese patients. The aim of this study was to investigate and compare small proximal (PGC, n = 111) with distal (DGC, n = 202) gastric carcinoma in 313 consecutive surgically resected small (<2 cm) gastric carcinomas diagnosed with the WHO criteria. PGC patients were significantly older (average age 63 years versus 59 in DGCs) with a male/female ratio of 3:1. Most tumours were clustered along the lesser curvature (74% in PGCs and 65% in DGCs). Compared to DGCs, PGCs showed a protruded gross pattern significantly more frequently and were significantly better differentiated with a significantly wider histomorphological spectrum. Surprisingly, PGCs were composed of significantly fewer signet-ring cell carcinomas (1% versus 16% in DGCs) but were significantly more deeply invasive, compared to DGCs. Lymph node metastasis was detected in 23% overall, but was significantly less frequent in PGCs (16%) than in DGCs (26%) (p < 0.05). However, the difference in survival between the two groups was not statistically significant. Our results demonstrate that in Chinese patients, PGCs display distinct clinicopathological characteristics, compared to DGCs.

Key words: Cardia, Chinese, gastric cancer, Helicobacter pylori.

Received 1 January, revised 10 April, accepted 20 April 2015

INTRODUCTION
Gastric carcinoma is a heterogeneous disease. For instance, a rising incidence of proximal gastric carcinoma (PGC) has been reported almost worldwide, in contrast to a declining trend of distal gastric carcinoma (DGC).1,2 Morphologically, PGCs display a wider variety of uncommon histological subtypes than the typical intestinal, diffuse, or mixed histology of DGCs.3-5 Differences in molecular underpinnings have also been reported. For example, HER2 and Sirt1 genes are more commonly expressed in PGCs than in DGCs.6-8 Gene expression arrays have shown variations in signal transduction pathways between PGC and DGC.6,7 Some authors provide evidence for two subtypes for PGCs: some are akin to oesophageal adenocarcinoma (EAC) and related to gastroesophageal reflux disease, whereas others are similar to DGC and associated with Helicobacter pylori infection and atrophic gastritis.8-11 Collectively, these observations favour PGC and DGC being different diseases. Despite recent advances in our understanding of PGC, detailed clinicopathological studies of PGC in populations at high risk for gastric carcinoma remain rare. Many previous investigations include large, advanced neoplasms that obliterate the landmark of the gastroesophageal junction (GEJ).3,12 This makes difficult a confident determination of the proximal gastric origin of a tumour. Complexity also stems from the controversial anatomical definition of the gastric cardia.13-15 However, the exact anatomical distribution of PGCs is important to define, since recent GEJ cancer staging guidelines, which appear to be adequate for Western patients, have been shown to be flawed for East Asian populations.16-17 Thus, the present study was aimed to systematically investigate PGCs and to compare their clinicopathological characteristics with DGCs in a homogenous Chinese patient population with high risk for gastric cancer but very low incidence of Barrett’s oesophagus and EAC.18 We specifically restricted our study to small PGCs measuring up to 2 cm in size to allow a better preservation of histological landmarks of the GEJ in order to eliminate any misclassification of gastric cancer as oesophageal in origin.

MATERIALS AND METHODS

Study group
All surgical pathology reports with a final diagnosis of gastric carcinoma from January 2004 through December 2011 were mined from the electronic pathology database of the Nanjing Drum Tower Hospital in China. Each report was reviewed for demographics, tumour gross and microscopic characteristics, and staging information. Inclusion criteria were: (1) surgically resected tumours with lymph node dissection; and (2) tumour size up to 2 cm in maximum dimension. Exclusion criteria included: (1) endoscopically resected tumours by mucosal resection or submucosal dissection without lymph node dissection; (2) tumour size larger than 2 cm; (3) no definitive invasion identified upon review of all histology slides; (4) tumours with the epicentre located in the distal oesophagus with a minor component of invasion into the proximal stomach; (5) tumour in the gastric stump from a patient with prior partial gastrectomy; (6)
the absence of tumour tissue blocks for recuts; (7) neoadjuvant therapy; and (8) a
distinct synchronous tumour detected within a minimal distance of 2 cm from the
main tumour.

Patient medical records including radiology and endoscopy reports, labora-
tory study results, and surgical operative notes were reviewed. In 30% of the
cases that were referred for surgery to the Nanjing Drum Tower Hospital but with
detailed pre-operative radiology and endoscopy performed at outside institutions,
the analysis was carried out principally on the local operative notes and
resection specimen pathology findings. Patients were followed up for
survival status through telephone or personal interview with the patient or
family members. Results were verified with the government citizen death
record. Patient consent for surgery and research was obtained in all cases
before surgical resection was carried out. The Medical Ethics Committee of the
Nanjing Drum Tower Hospital approved the study protocol.

Definition of carcinoma location, type, grade, and staging

All cases were divided into PGC and DGC groups, based on the location of
tumour’s epicentre. PGCs were defined as tumours with the epicentre located
within 3 cm below the GEJ. All other tumours distal to this 3 cm line were
considered DGCs.

Gastrectomy specimens were routinely processed. Partial gastrectomy for
PGCs was carried out by an abdominal trans-hiatal approach with at least 2 cm of
distal oesophagus resected. Tumour gross characteristics were obtained from
pathology reports, including size, shape, surface, colour, consistency, the
relationship to GEJ, resection margin, and the quality of adjacent gastric or
oesophageal mucosa. Gross and endoscopic digital images were reviewed, if
available. All tumours were macroscopically classified into five patterns, based
on previously published classification: (1) protruding with a broad base; (2)
elevated with a rough surface; (3) flat without elevation or depression; (4)
depressed with an eroded surface; and (5) excavated with an ulcerated centre and
a defined border.

All tumours were classified as adenocarcinoma, adenosquamous and mucino-
cus carcinomas, carcinoma with lymphoid stroma, or poorly cohesive (includ-
ing signet-ring cell) carcinomas, using the WHO scheme. A well-
differentiated tumour exhibited well-formed papillae or tubules in over 95% of the
tumour, in contrast to a poorly differentiated carcinoma with irregular or
indiscernible glands in less than 50% of the tumour. In cases with morphological
features suspicious for neuroendocrine carcinoma, adenocarcinoma with pan-
creatic differentiation, and carcinoma with lymphoid stroma, appropriate
immunohistochemical (i.e., synaptophysin, chromogranin A, CD56, CD57, or
chymotrypsin) and in situ hybridisation evaluations for Epstein–Barr virus (EBV)
were performed with standard protocols.

Lymphovascular and perineural invasion and the status of resection margins
were recorded. In cases with no carcinoma identified in routine sampling, the
entire gastric mucosa was submitted for histological examination.

All tumours were staged by the 7th edition of the American Joint Committee
on Cancer (AJCC) staging guidelines.

Evaluation of adjacent uninvolved gastric mucosa

The presence or absence of chronic active gastritis, metaplasia (i.e., intestinal or
pancreatic), Helicobacter pylori infection (based on haematoxylin-eosin and
Giemsas stains), and atrophy (defined as either a reduced number of glands or
intestinal metaplasia) were recorded, based on the WHO definitions.

Immunohistochemistry

Using conventional methods, immunohistochemistry was performed on
selected cases. The antibodies used were purchased from government-approved
vendors. Appropriate positive and negative controls were included in each
run. Two experienced pathologists, blinded to the patient’s clinical infor-
mation, reviewed each immunostain independently. The discrepancy between
readers was minimal, when present, and resolved by consensus.

In situ hybridisation for EBV-encoded small ribonucleic acid-1

EBV in situ hybridisation, as described previously with minimal modification,21
was carried out on tumour sections that were sequentially deparaffinised,
rehydrated through graded ethanol solutions in a decreasing order down to
water, then predigested with 0.4% papain, and hybridised overnight at 37°C
with digoxigenin-labelled probes, based on the manufacturer’s instructions
(Zhongshan Jingqiao, China). The positive control consisted of Burkitt’s
lymphoma, and a normal lymph node served as the negative control. Both
controls were run in each batch to ensure validity.

Statistical analysis

Patient age, gender, Helicobacter pylori status, tumour location, gross pattern,
site, grade, type, stage, lymphovascular and perineural invasion, adjacent
uninvolved mucosa, and resection margin status were analysed and compared
between PGC and DGC groups with the Chi-square or Fisher’s exact test, when
appropriate. Survival rates were estimated by the Kaplan–Meier method with a
log rank test. The Cox regression analysis was used to identify risk factors for
overall survival. All analyses were carried out with the Statistical Package for
Social Sciences (Version 13; SPSS, USA). p values <0.05 were defined as
statistically significant.

RESULTS

Within the 8-year study period, 313 consecutive patients met the
inclusion criteria. The patients were divided into PGC
(n = 111, 35%) and DGC (n = 202, 65%) groups (Table 1).
The average number of tumour-bearing histology sections
reviewed was 3.5 (range 1–13) per case.

Demographics

Male gender was predominant in both PGC and DGC groups,
but the male/female patient ratio was significantly higher in
PGCs than in DGCs (3.1 versus 1.7, p < 0.05). The average age
of patients was also significantly older in PGCs (63 years) than
in DGCs (59 years, p < 0.05). There were no patients younger
than the age of 40 in the PGC group.

Tumour distribution and macroscopic characteristics

Overall, the majority (68%) of tumours arose along the lesser
curvature, mainly in two areas, the cardia and antro (Table 1
and Fig. 1). The remaining tumours were scattered in the
corpus, pylorus, and the greater curvature.

Macroscopically (Table 1), excavated tumours were most
frequent (61%) overall, but significantly less so in PGCs
(p < 0.01). Protruding tumours (Fig. 2) were generally infre-
quent (7%), but more common in the PGC group than in the
DGC (p < 0.0001). Elevated, flat, and depressed patterns were
less common in PGCs than in DGCs.

Table 1 Comparison of tumour gross characteristics

| Gross feature | PGC (%) | DGC (%) | p     |
|---------------|---------|---------|-------|
| Size (cm)     | 1.6 ± 0.47 | 1.5 ± 0.5 | NS    |
| Range         | 0.3–2.0 | 0.3–2.0 |        |
| Epitom liability |        |         |       |
| Gastroesophageal junction | 10 (9) | – |        |
| Fundus        | 5 (5)   | –       |       |
| Lesser curvature | 82 (74) | 132 (65) | NS    |
| Greater curvature  | 6 (5)  | 16 (8)  | NS    |
| Anterior/posterior wall | 8 (7)  | 7 (4)   | NS    |
| Antrum/anterior  | –      | 18 (9)  |       |
| Incisura      | –       | 14 (7)  |       |
| Corpus        | –       | 6 (3)   |       |
| Pylorus       | –       | 9 (4)   |       |
| Gross feature |         |         |       |
| Protruded     | 16 (15) | 6 (3)   | 0.0001|
| Elevated      | 14 (13) | 18 (9)  | NS    |
| Flat          | 6 (5)   | 12 (6)  | NS    |
| Depressed     | 18 (16) | 27 (13) | NS    |
| Excavated     | 57 (51) | 139 (69) | 0.005 |

PGC, distal gastric carcinoma; NS, not significant; PGC, proximal gastric
carcinoma; SD, standard deviation.
Histopathology of small proximal gastric carcinomas

Compared to DGCs (Table 2), PGCs were significantly better differentiated \( (p < 0.001) \) and exhibited a wider histopathological spectrum. While tubular adenocarcinoma was most common, pure and mixed mucinous carcinomas were predominant among PGCs. Mixed squamous (Fig. 3A) and neuroendocrine carcinomas were found only in PGCs. Mixed squamous cell \( (p < 0.001) \) and neuroendocrine \( (p < 0.001) \) carcinomas were found only in PGCs. Papillary adenocarcinoma (Fig. 3B) occurred significantly more frequently in PGCs \( (p < 0.0001) \). A small proportion \( (9\%) \) of PGCs arose in mucous glands at the GEJ and showed an expansile growth pattern with anastomosing glandular architecture without evidence of columnar-lined oesophagus with intestinal metaplasia (Fig. 3C). Micropapillary \( (p < 0.001) \), pure mucinous, pure neuroendocrine (Fig. 3E) carcinomas, and carcinoma with lymphoid stroma \( (p < 0.05) \) were also more common in PGCs than in DGCs, but the differences were not statistically significant. In contrast, pure and mixed signet-ring cell carcinomas were significantly less common in PGCs than in DGCs \( (p < 0.001) \). Poorly cohesive carcinoma \( (p < 0.05) \) was also less common in PGCs than in DGCs (Table 2). There were no significant differences between the two groups in tumour size, lymphovascular and perineural invasion, and resection margin status.

Histopathology of adjacent gastric mucosa

The frequency of chronic active gastritis, intestinal metaplasia and atrophy was similar in both groups (Table 2). Helicobacter pylori infection was significantly lower in PGCs than in DGCs \( (p < 0.001) \). The frequency of Helicobacter pylori infection was significantly lower in PGCs than in DGCs \( (p < 0.001) \).

Table 2 Comparison of histopathology

| Tumour characteristics | PGC (%) \((n = 111)\) | DGC (%) \((n = 202)\) | \(p\) |
|------------------------|----------------------|---------------------|------|
| Tumour differentiation |                      |                     |      |
| Well                   | 22 (20)              | 17 (8.5)            | 0.0002 |
| Moderately             | 45 (41)              | 59 (29)             |      |
| Poorly                 | 44 (39)              | 126 (63)            |      |
| Histology type         |                      |                     | 0.0000|
| Adenocarcinoma         |                      |                     |      |
| Tubular                | 50 (45)              | 106 (52)            |      |
| Papillary              | 34 (30)              | 10 (5)              |      |
| Mixed signet-ring cell | 5 (5)                | 32 (16)             |      |
| Mixed mucinous         | 5 (5)                | 2 (1)               |      |
| Mixed squamous cell    | 2 (2)                | 0                   |      |
| Mixed neuroendocrine   | 2 (2)                | 0                   |      |
| Poorly cohesive adenocarcinoma* | 2 (2) | 18 (9) |      |
| Signet-ring cell carcinoma | 1 (1)            | 32 (16)             |      |
| Mucinous carcinoma     | 2 (2)                | 0                   |      |
| Carcinoma with lymphoid stroma | 2 (2) | 1 (0.5) |      |
| Neuroendocrine carcinoma | 5 (2)                | 3 (1.5)             |      |
| Perineural invasion    | 23 (21)              | 44 (21)             |      |
| Lymphovascular invasion | 22 (20)            | 45 (22)             |      |
| Positive surgical resection margin | 3 (3) | 3 (1.5) |      |
| Adjacent gastric mucosa|                      |                     |      |
| Chronic active inflammation | 107 (96)          | 199 (98.5)          |      |
| Atrophic mucosal/intestinal metaplasia | 97 (87) | 176 (87) |      |
| Helicobacter pylori    | 59 (53)              | 150 (74.25)         | 0.0005|
| Pancreatic metaplasia  | 27 (24)              | 0                   |      |

DGC, distal gastric carcinoma; NS, not significant; PGC, proximal gastric carcinoma; SD, standard deviation.

*Excluding signet-ring cell carcinoma.

Patient survival

Sixty-five \( (21\%) \) patients, 28 \( (25\%) \) in the PGC group and 37 \( (17\%) \) in the DGC, were lost to follow-up and excluded from further analysis.
the survival analysis. At the last interview, 24 (10%) patients had died, eight (7%) in the PGC group and 16 (8%) in the DGC. Although the mean survival in PGCs [84.7 months, 95% confidence interval (CI) 79.3–90.2] was shorter than that in DGCs (94.4 months, 95% CI 89.6–99.1), the difference between the two groups was not statistically significant ($p = 0.6$) (Fig. 4). There was no significant difference in survival between the two groups in stage-by-stage or year-by-year comparisons. Multivariate analysis identified age $\geq 61$ years [odds ratio (OR) 2.6; $p < 0.05$], pT3 (OR 13.3; $p < 0.001$), and pT4 (OR 3.4; $p < 0.05$) tumours as significant independent risk factors for worse overall survival.

**DISCUSSION**

In line with previous studies, our data show a predominant distribution pattern of small gastric carcinoma along the lesser curvature for both PGCs and DGCs. However, compared to DGCs, PGCs demonstrate the following distinct clinicopathological characteristics: (1) elderly male predominance; (2) more protruded and fewer excavated macroscopic growth patterns; (3) better histological differentiation and a wider morphological spectrum but fewer signet-ring cell carcinomas; (4) deeper invasion but fewer lymph node metastases; and (5) lower frequency of *Helicobacter pylori* infection and exclusive association with pancreatic metaplasia. All together, we believe that these data, although yet insufficient to support classifying PGC as a unique subtype of gastric cancer, underscore the difference between two topographically distinct gastric carcinomas.

In recent years, some investigators have proposed that PGCs be considered as part of the distal EAC spectrum, based on the assumption that PGC may originate from undetected short-segment Barrett’s oesophagus. The results from the present cohort and a previous study in the same Chinese patient population have shown otherwise. In Chinese patients, distal oesophageal Barrett’s oesophagus and EAC are rare, but PGC is common and histologically heterogeneous. In contrast, almost all distal EACs are pure adenocarcinomas of the intestinal phenotype (Lauren classification). Furthermore, the AJCC pathological staging rules for GEJ cancer have been found deficient when applied to PGCs with oesophageal invasion in both East Asian and European populations. The discrepancy may result, at least partially, from misclassification...
Chinese patients, most Siewert’s type II tumours (1 cm above and 2 cm below the GEJ) are likely to represent proximal gastric, but not distal oesophageal, tumours. In addition, several Asian investigators have shown that Siewert’s type III tumours (2–5 cm below the GEJ) present similar clinicopathological characteristics to DGCs. Consequently, given the discrepancies and overlapping between these landmarks (developed primarily with the data from Caucasian patients) and the results obtained from Chinese patients, we chose to use tumour epicentre at 3 cm below the GEJ as a new landmark for PGC. Compared to DGCs, PGCs more often exhibit a macroscopically protruding pattern. PGCs are also in general better differentiated and poorly cohesive carcinomas are unusual. However, PGCs are more deeply invasive, a characteristic reported as an independent predictor of worse survival in several Japanese series. Finally, pancreatic metaplasia was frequently detected adjacent to PGCs, a finding not described in association with distal EAC. Perhaps one of the most striking yet unexpected findings is a high overall lymph node metastasis rate of 23%, which is much higher than that reported in Japanese series evaluating early small carcinomas (≤2 cm in size) with poor prognostic indicators (ulcerative gross appearance and undifferentiated carcinoma histology). In general, the prognosis of PGCs is reported to be worse than that of DGCs. This is directly related to the more advanced pT stage, as previously described in Korean and Chinese patients. Furthermore, in this cohort, advanced PGCs cases are rare (10% as pIII and none as pIV), but patients show shorter survival, compared to DGCs, as pIV), but patients show shorter survival, compared to DGCs, although the difference in survival is not statistically significant. This observation, in our opinion, suggests the need for a large-scale survival study of PGC patients in order to better evaluate their prognosis and predisposing factors.

Given the similar frequency of chronic active gastritis with intestinal metaplasia and atrophy in the mucosa surrounding both PGCs and DGCs, Helicobacter pylori infection remains the primary risk factor for gastric carcinomas in the Chinese population. However, since the actual incidence of Helicobacter pylori infection in PGCs is smaller, other risk factors may play important roles in the development of PGCs. Those risk

| Pathological staging (pTNM) | Proximal (PGC, %) | Distal (DGC, %) | p (PGC vs DGC) |
|-----------------------------|------------------|----------------|----------------|
| Total cases                 | 111              | 202            | 0.0343         |
| pT                          |                  |                |                |
| 0                           | 93 (84)          | 149 (74)       | 0.048          |
| 1                           | 10 (9)           | 26 (13)        |                |
| 2                           | 6 (6)            | 15 (7.5)       |                |
| 3                           | 2 (2)            | 12 (6)         |                |
| pN                          |                  |                |                |
| 0                           | 111 (100)        | 201 (100)      | NS             |
| 1                           | 0                | 1 (0.5)        |                |
| Summary stage               |                  |                |                |
| I                           | 84 (76)          | 140 (70)       |                |
| IA                          | 56 (50)          | 109 (54)       |                |
| IB                          | 28 (25)          | 31 (15)        |                |
| II                          | 16 (14)          | 35 (17)        |                |
| IIA                         | 10 (9)           | 27 (13.5)      |                |
| IIB                         | 6 (6)            | 8 (4.5)        |                |
| III                         | 11 (10)          | 26 (13)        |                |
| IIIA                        | 1 (1)            | 6 (3)          |                |
| IIIB                        | 6 (6)            | 13 (6.5)       |                |
| IIIC                        | 4 (4)            | 7 (4)          |                |
| IV                          | 0                | 1 (0.5)        |                |

DGC, distal gastric carcinoma; NS, not significant; PGC, proximal gastric carcinoma.

Fig. 4 Kaplan–Meier survival curves of patients with PGC or DGC tumours and staged as gastric carcinoma (AJCC 7). (A) There was no statistically significant difference between the PGC and DGC groups in overall survival outcomes. (B) Patients with PGCs were stratified according to different pathological stages; the difference in survival stratification was statistically significant. (C) Patients with DGC demonstrated an excellent stage-by-stage, statistically significant survival stratification difference (p < 0.0001).
factors may include tobacco abuse (epidemic in China) and obesity. Of note, two recent meta-analyses emphasise the relationship between increased body mass index and the risk of gastric cancer development, especially in the proximal stomach.39,40

Finally, using comparative genomic hybridisation, Japanese researchers have described statistically significant chromosomal gains and losses in 35 PGCs, compared to 67 DGCs.41 In PGCs, the most common deletion is on chromosome 18q, where the tumour suppressor smad gene (a key regulator of the transforming growth factor-β signalling pathway) is located.42 Recently, Canadian researchers have reported, in an abstract form, the presence of mutational differences between gastric cardia (PGC) and non-cardia (DGC) carcinomas.3 Their findings are confirmed by the most recent data on comprehensive molecular characterisation of gastric carcinoma,39 supporting the concept of pathobiological diversity between PGCs and DGCs.7

The major limitation of this retrospective study includes inherent deficiency in data uniformity, such as collection of tumour gross images, standardisation of endoscopic investigation with biopsies, and completion of survival investigation. A further limitation is the lack of results on adjuvant therapy, which could confound the survival data. Although such variables are difficult to control, the main findings of the study are unlikely to be adversely affected, because of the large sample size, strict exclusion criteria, and detailed histopathological investigations.

In summary, based on the evidence acquired from present and previous studies,3,6,7,17,25 PGC can be characterised as an elderly male predominant, heterogeneous gastric carcinoma, frequently presenting with better differentiation, deeper penetration, and fewer nodal metastases, in comparison to DGC. Altogether, these results detail striking clinicopathological differences between PGCs and DGCs in the Chinese population. However, the data are yet insufficient to support classifying PGC as a unique subtype of gastric cancer.

Acknowledgements: The major results of this study were published in an abstract form in Gastroenterology 2012; 142 (5, Suppl 1): S627.

Conflicts of interest and sources of funding: This research project was financed partially by grants from the Science and Technology Development Project of the Nanjing City (ZKX05013, ZKX07011) in China, and a special grant from the Nanjing Drum Tower Hospital, Nanjing, China. JSG is supported by the Department of Veterans Affairs Office of Research and Development through a Career Development Award-2. The authors state that there are no conflicts of interest to disclose.

Address for correspondence: Qin Huang, MD, PhD, Department of Pathology and Laboratory Medicine, Veterans Affairs Boston Healthcare System and Harvard Medical School, 1400 VFW Parkway, West Roxbury, MA 02132, USA. E-mail: Qinhuang0122@gmail.com; qin.huang@va.gov

References
1. Crane SJ, Locke GR III, Harmsen WS, et al. The changing incidence of oesophageal and gastric adenocarcinoma by anatomic sub-site. Alim Pharm Ther 2007; 25: 447–53.
2. Shi J, Sun Q, Xu BY, et al. Changing trends in proportions of small (≤2cm) proximal and non-proximal gastric carcinomas treated at a high-volume tertiary medical center in China. J Dig Dis 2014; 15: 359–66.
3. Huang Q, Fun XS, Agoston AT, et al. Comparison of gastroesophageal junction carcinomas in Chinese versus American patients. Histopathology 2011; 59: 188–97.
4. Shi J, Sun Q, Yu HP, et al. Unique clinicopathologic features of early proximal gastric cancer diagnosed with WHO criteria: implications for endoscopic resection. Gastroenterology 2014; 146 (Suppl 1): S515.
5. Fan XS, Chen JY, Li CF, et al. Differences of HER2 over-expression between proximal and distal gastric cancers in the Chinese population. World J Gastroenterol 2013; 19: 3316–23.
6. Shah MA, Khanin R, Tang L, et al. Molecular classification of gastric cancer: a new paradigm. Clin Cancer Res 2011; 17: 2693–701.
7. Li-Chang HH, Schaeffer DF, Ng Y, et al. Targeted deep sequencing reveals both mutational differences and similarities between gastric cardia and non-cardia adenocarcinomas. Mod Pathol 2014; 27 (Suppl 2): 191A.
8. Hansen S, Vollset SE, Derakhshan MH, et al. Two distinct aetiologies of cardia cancer: evidence from premorbid serological markers of gastric atrophy and Helicobacter pylori status. Gut 2007; 56: 918–25.
9. Derakhshan MH, Malekzadeh R, Watabe H, et al. Combination of gastric atrophy, reflux symptoms and histological subtype indicates two distinct aetiologies of gastric cancer. Gut 2008; 57: 298–305.
10. Ken JS, Kamangar F, Qiao YL, et al. Serum pepsinogen and risk of gastric and oesophageal cancers in the General Population Nutrition Intervention Trial cohort. Gut 2009; 58: 636–42.
11. CollC KE, Gjon JJ. Aetiology and classification of adenocarcinoma of the gastro-esophageal junction/cardia. Gut 2010; 59: 282–4.
12. Chandrasoma P, Wickramasinghe K, Ma Y, et al. Adenocarcinomas of the distal oesophagus and “gastric cardia” are predominantly esophageal carcinomas. Am J Surg Pathol 2007; 31: 569–75.
13. Chandrasoma P, Makarewicz K, Wickramasinghe K, et al. A proposal for a new validated histological definition of the gastroesophageal junction. Hum Pathol 2006; 37: 40–7.
14. Huang Q. Controversies of cardiac glands in the proximal stomach: a critical review. J Gastroenterol Hepatol 2011; 26: 450–5.
15. Owen DA. Stomach. In: Sternberg SS, editor. Histology for Pathologists. 2nd ed. New York: Raven Press, 1997: 481–93.
16. Suh YS, Han DS, Song SH, et al. Should adenocarcinoma of the esophagogastric junction be classified as esophageal cancer? A comparative analysis according to the seventh AJCC TNM classification. Ann Surg 2012; 255: 908–15.
17. Huang Q, Shi J, Feng AN, et al. Gastric cardiac carcinomas involving the esophagus are more adequately staged as gastric cancers by the 7th edition of the American Joint Commission on Cancer staging system. Mod Pathol 2011; 24: 138–46.
18. Huang Q, Shi J, Sun Q, et al. Distal esophageal carcinomas in Chinese patients vary widely in histopathology, but adenocarcinomas remain rare. Hum Pathol 2012; 43: 2138–48.
19. Li L, Fan GL, Shen Q. A pathologic study of early carcinoma of gastric cardia. (Chinese.) Zhongguo Zhong Liu Za Zhi 1982; 4: 93–7.
20. Lauwers GY, Carmeiro F, Graham DV, et al. Gastric carcinoma. In: Bosman FT, Carneiro F, Heuban RH, Theise ND, editors. WHO Classification of Tumours of the Digestive System. Lyon IARC Press, 2010: 48–58.
21. American Joint Committee on Cancer. AJCC Cancer Staging Manual. 7th ed. New York: Springer, 2007; Chapter 10, Esophagus and esophageo-gastric junction.
22. Huang Q, Gold JS, Shi J, et al. Pancreatic acinar-like adenocarcinoma of the proximal stomach involving the esophagus. Hum Pathol 2012; 43: 911–20.
23. Chang KL, Chen YY, Shibata D, et al. Description of an in situ hybridization methodology for detection of Epstein-Barr virus RNA in paraffin-embedded tissues, with a survey of normal and neoplastic tissues. Diagn Mol Pathol 1992; 1: 246–55.
24. Tajima Y, Nakamichi Y, Yoshino T, et al. Clinicopathological study of early adenocarcinoma of the gastric cardia: comparison with early adenocarcinoma of the distal stomach and esophagus. Oncology 2001; 61: 1–9.
25. Gertler R, Stein HH, Loos M, et al. How to classify adenocarcinoma of the esophagogastric junction as esophageal or gastric cancer? Am J Surg Pathol 2011; 35: 1512–22.
26. Smith RR, Hamilton SR, Boimott JK, et al. The spectrum of carcinoma arising in Barrett’s esophagus. A clinicopathologic study of 26 patients Am J Surg Pathol 1984; 8: 563–73.
27. Ekstrom AM, Signorelli LB, Hansen LE, et al. Evaluating gastric cancer misclassification: a potential explanation for the rise in cardia cancer incidence. J Natl Cancer Inst 1999; 91: 786–90.
28. Siewert JR, Stein HH, Feith M. Adenocarcinoma of the esophagogastric junction. Scand J Surg 2006; 95: 260–9.
29. Yasua N, Miyake H, Yamada T, Ebata T, Nimura Y, Hattori T. Clinicopathologic comparison of Siewert type II and III adenocarcinomas of the gastroesophageal junction. World J Surg 2006; 30: 364–71.
30. Hasegawa S, Yoshikawa T, Cho H, et al. Is adenocarcinoma of the esophagogastric junction different between Japan and western countries?
The incidence and clinicopathological features at a Japanese high-volume cancer center. *World J Surg* 2009; 33: 95–103.

31. Chung JW, Lee GH, Choi KS, *et al.* Unchanging trend of esophagogastric junction adenocarcinoma in Korea: experience at a single institution based on Siewert’s classification. *Dis Esophagus* 2009; 22: 676–81.

32. Fang WL, Wu CW, Chen JH, *et al.* Esophagogastric junction adenocarcinoma according to Siewert classification in Taiwan. *Ann Surg Oncol* 2009; 16: 3237–44.

33. Hosokawa Y, Kinoshita T, Konishi M, *et al.* Clinicopathological features and prognostic factors of adenocarcinoma of the esophagogastric junction according to Siewert classification: experiences at a single institution in Japan. *Ann Surg Oncol* 2012; 19: 677–83.

34. Hirase D, Gotoda T, Miyata S, *et al.* Incidence of lymph node metastasis and the feasibility of endoscopic resection for undifferentiated-type early gastric cancer. *Gastric Cancer* 2009; 12: 148–52.

35. Ito H, Inoue H, Ikeda H, *et al.* Clinicopathological characteristics and treatment strategies in early gastric cancer: a retrospective cohort study. *J Exp Clin Cancer Res* 2011; 30: e117.

36. Piso P, Werner U, Lang H, *et al.* Proximal versus distal gastric carcinoma—what are the differences? *Ann Surg Oncol* 2000; 7: 520–5.

37. Park JC, Lee YC, Kim JH, *et al.* Clinicopathological features and prognostic factors of proximal gastric carcinoma in a population with high Helicobacter pylori prevalence: a single-center, large-volume study in Korea. *Ann Surg Oncol* 2010; 17: 829–37.

38. Yao D, Wang Y, Xue L, *et al.* Different expression pattern and significance of p14ARF-Mdm2-p53 pathway and Bmi-1 exist between gastric cardia and distal gastric adenocarcinoma. *Hum Pathol* 2013; 44: 844–51.

39. Turati F, Tramacere I, La Vecchia C, *et al.* A meta-analysis of body mass index and esophageal and gastric cardia adenocarcinoma. *Ann Oncol* 2013; 24: 609–17.

40. Chen Y, Liu L, Wang X, *et al.* Body mass index and risk of gastric cancer: a meta-analysis of a population with more than ten million from 24 prospective studies. *Cancer Epidemiol Biomarkers Prev* 2013; 22: 1395–408.

41. Kimura Y, Noguchi T, Kawahara K, *et al.* Genetic alterations in 102 primary gastric cancers by comparative genomic hybridization: gain of 20q and loss of 18q are associated with tumor progression. *Mod Pathol* 2004; 17: 1328–37.

42. Nam KT, O’Neal R, Lee YS, Lee YC, Coffey RJ, Goldenring JR. Gastric tumor development in Smad3-deficient mice initiates from forestomach/glandular transition zone along the lesser curvature. *Lab Invest* 2012; 92: 883–95.

43. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. *Nature* 2014; 513: 202–9.